Generic Pharmaceuticals Businesses for Sale and Investment

The business is a non-operational API manufacturing company and has remained inactive for the past 7 months. - It previously manufactured enzymes and probiotics and served 30+ B2B clients. - The production capacity is 20 MT per month for enzymes and 20 MT per month for probiotics. - The business is registered under GST. MSME with a drug manufacturing license and factory license. It does not have a USFDA approval.

Private pharmaceutical manufacturing company with over three decades of operating history and WHO-GMP certified manufacturing facilities. - Manufactures pharmaceutical injections, eye drops, and ointments for regulated and semi-regulated markets across 20 countries. - Has secured more than 250 product approvals, demonstrating strong regulatory capabilities and a diversified product portfolio. - The business has an incorporation certificate and GST certificate. - The company operates a highly automated pharmaceutical manufacturing facility, enabling high production volumes and revenue generation with a relatively lean workforce. - Not a USFDA approved company.

Private pharmaceutical manufacturing company with over three decades of operating history and WHO-GMP certified manufacturing facilities. - Manufactures pharmaceutical injections, eye drops, and ointments for regulated and semi-regulated markets across 20 countries. - Has secured more than 250 product approvals, demonstrating strong regulatory capabilities and a diversified product portfolio. - The business has an incorporation certificate and GST certificate. - The company operates a highly automated pharmaceutical manufacturing facility, enabling high production volumes and revenue generation with a relatively lean workforce. - Not a USFDA approved company.

Operates a pharmaceutical manufacturing company producing a wide range of formulations for domestic and international markets. - Manufactures injectables (50% of revenue), tablets and capsules (30%), and liquids and ointments (20%). - Supplies products to hospitals, distributors, and pharmaceutical marketers across India and 40+ export markets. - Maintains a strong portfolio of over 1,400 registered products with an additional pipeline of approximately 1,300 products. - Generates around 40% of revenue from exports, reflecting established global market presence. - Equipped with certified manufacturing facilities compliant with WHO-GMP and ISO standards. - Backed by over two decades of operational experience in pharmaceutical manufacturing. - Operates scalable infrastructure with capacity for expansion and increased production. - Does not require USFDA approval for its current operations and target markets. - Registered with the Ministry of Corporate Affairs (MCA) and holds valid GST certification.

• Manufacturer and exporter of homeopathic OTC products, offering a wide portfolio including single remedy pills, dilutions, tablets, pellets, family kits, and blank sugar globules. • Operates as a digitally native, direct-to-consumer (D2C) brand with sales infrastructure built for its own website and major US marketplaces such as Amazon, eBay, and Walmart. • Holds a rare multinational structure with legal entities in the United States, India, and Canada, enabling global operations and regulatory alignment. • Manufacturing facility in India is US FDA registered and has undergone multiple inspections, with only minor observations in the latest review and clearance expected to resume exports. • Owns a US FDA Drug Master File (Type IV) for homeopathic blank pellets, positioning the business as a qualified global supplier of pharmaceutical-grade excipients. • Portfolio includes thousands of OTC SKUs listed with the US FDA, reflecting significant product depth and regulatory groundwork. • Brand is a registered trademark in the United States, strengthening intellectual property protection and market positioning. • Demonstrates strong customer validation through high ratings across major marketplaces and its own platform, indicating product acceptance despite pre-revenue status. • US-based fulfillment center is FDA-inspected with no observations, capable of handling large-scale order volumes and compliant with cGMP standards including recalls and complaint handling. • Backed by a founding team with decades of domain experience in homeopathy and established industry presence. • Built a scalable proprietary e-commerce infrastructure integrated with production systems and third-party platforms, ready to support high SKU and order volumes. • Currently pre-revenue with no sales recorded yet from the India facility; regulatory processes including US FDA inspection are in progress.

Pharmaceutical manufacturing company producing a wide range of formulations for domestic and international markets. - Operates on a B2B model supplying distributors, pharma companies, and healthcare businesses. - Serves 100+ clients globally and exports products to more than 20 countries. - Handles approximately 30–35 orders per month across different markets. - Manufacturing facility is WHO-GMP certified and designed to meet international quality standards. - Strong presence in ROW (Rest of World) markets with ongoing export operations. - Registered under the Ministry of Corporate Affairs and holds valid GST registration. - Holds required pharmaceutical manufacturing approvals including WHO-GMP certification and USFDA compliance for export-related operations.

Business will operate from a self-owned facility on leased land. - The new plant, Designed to meet USFDA & EU-GMP requirements, is a Greenfield project with a land size of 240,000 sq ft on a 99-year lease. - The built-up area spans 90,000 sq ft and is located in Dewas. - Its scope includes manufacturing oral powder sachets, effervescent tablets, oral liquids, tablets, and capsules, all designed for global compliance. - The promoter have extensive pharmaceutical manufacturing, marketing & distribution experience and an able leadership and marketing team.

• Established pharmaceutical formulation manufacturing unit located in Una district, Himachal Pradesh. • Operates from a built-up facility of approximately 21,000 sq. ft. across two floors. • Infrastructure is expandable up to double the existing built-up area. • Separate, dedicated production blocks for general formulations and beta-lactam formulations. • Manufactures tablets, capsules, liquids, ointments, and dry syrups. • Licensed to manufacture approximately 1,000 formulations across multiple therapeutic segments. • Product portfolio spans general, diabetic care, neuro-psychiatry, nephrology, gynaecology, orthopaedic, pediatric, and other specialities. • No NSQ (Not of Standard Quality) record for any product to date. • Installed annual capacity supports turnover of INR 50–60 crore in a single shift. • Currently operates at around 25% capacity with an annual turnover of INR 12–14 crore. • Over 80% of revenue is generated through third-party manufacturing contracts. • Maintains strong working capital discipline with 100% debtor recovery within 60 days. • Enjoys favourable creditor terms with approximately 90-day payment cycles. • Equipped with a fully functional in-house Quality Control laboratory. • QC facilities include chemical, instrumental, and microbiological testing along with stability study instruments. • Offers significant growth potential with up to threefold scale-up through higher capacity utilization. • Holds GMP and GLP certifications compliant with revised Schedule M standards. Does not hold USFDA approval.